

**Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan**

***Consob approves the Supplement to the Registration Document, the Information Note and the Summary Note relating to the Share Capital Increase***

Milan (Italy), 25 March 2015 – MolMed S.p.A. (“**MolMed**”) announces that today Consob approved the supplement to the Registration Document, the Information Note and the Summary Note relating to the offer on a pre-emptive basis and the admission to trading on the MTA (*Mercato Telematico Azionario*) organised and managed by Borsa Italiana S.p.A. of the ordinary shares of MolMed as filed with Consob on 6 March 2015, upon notice of approval dated 6 March 2015 (the “**Supplement**”).

The Supplement contains the update and the integration of the information contained in the Registration Document, the Securities Note and the Summary Note regarding the resignation of Prof. Riccardo Cortese as disclosed on 19 March 2015 from the office of independent non-executive member of the Board of Directors and of member of the Remuneration committee, effective from 1st April 2015. In such respect, it is pointed out that, on the same date, the Board of Directors resolved upon the appointment of the director Mario Masciocchi as member of the Remuneration committee, effective from 1<sup>st</sup> April 2015.

Moreover, the Supplement updates and supplements the information contained in the Registration Document, the Securities Note and the Summary Note regarding the stipulation of a strategic agreement with GlaxoSmithKline disclosed to the market on 20 March 2015, on the basis of which MolMed will supply development, production and technological transfer services aimed at the clinical application of gene therapies based on viral vector cellular transduction.

As part of the agreement, MolMed will provide its expertise in process development and its manufacturing competencies and capacity for the production of viral vectors and cell transduction.

In accordance with Art. 95-bis, paragraph 2 of Italian Legislative Decree no. 58/1998, we hereby inform any investors who have agreed to subscribe the Shares, in the period running from 09 March 2015 to the date on which the Supplement is published (inclusive), that they have the right to withdraw their acceptance within two working days of the date on which the Supplement is published. In such respect, the offer period is extended to 30 March 2015.

The Supplement will be made available in accordance with applicable laws at the registered office of MolMed, in Milan (Italy), via Olgettina, n. 58, and on MolMed’s website ([www.molmed.com](http://www.molmed.com)).

---

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

**NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN**

This communication does not constitute an offer or an invitation to subscribe for or purchase any Securities. The securities referred to herein have not been registered and will not be registered in the United States

---

**FROM GENES TO THERAPY**

**MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325  
info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

**Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan**

under the U.S. Securities Act of 1933, as amended (the "Securities Act") , or in Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would require the approval of local authorities or otherwise be unlawful. The securities may not be offered or sold in the United States or to U.S. persons unless such securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.

***About MolMed***

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

***For further information:*****Marina Del Bue**

**General Manager Corporate Governance & Administration  
Investor Relations Director *ad int.***

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Press agent****Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: [ferrari@secrp.it](mailto:ferrari@secrp.it)

**DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.*